Organization | Kawasaki Medical University

Kawasaki Medical University Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Kurashiki Japan (1970)

Organization Overview

First Clinical Trial

2007

NCT01263483

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2014

Timeline

NOW

Now

Alternative names

Department of Medicine, Kawasaki Medical School | Department of pediatrics, Kawasaki Hospital, Kawasaki Medical School

Active Ingredients

Drugs in Phase 3 Trials (5)

alogliptin (nesina) (9 trials)

glimepiride (amaryl) (3 trials)

pioglitazone (actos) (2 trials)

sitagliptin (januvia) (3 trials)

voglibose (4 trials)

Drugs in Phase 2 Trials (4)

dpt-ipv (1 trial)

haemophilus b conjugate vaccine diphteria crm197 protein conjugate (Menveo) (1 trial)

haemophilus influenzae type b conjugate vaccine (PedvaxHIB) (1 trial)

z-338 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Dyspepsia (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 12
# of Trial APIs: 9